UBS House View

Chief Investment Office WM 10 December 2015

Monthly Letter

The 2016 outlook

Equities look set for a positive year, supported by continued global growth, rising earnings, healthy corporate balance sheets, and accommodative central banks.

Years ahead

The turn of the year is a good time to look further into the future. Investors can achieve higher returns by allocating part of their portfolio to longer-term trends and riding out periods of market volatility.

Multi-decade trends

The growing global population, aging societies, and urbanization all have important implications for investors and present attractive investment opportunities in food, health, and infrastructure.

Asset allocation

For the coming year we favor Japanese and Eurozone stocks, which enjoy the most appealing combination of healthy profit growth and supportive monetary policy.



Mark Haefele Global Chief Investment Officer Wealth Management

Back to the future

In 1985, my favorite movie was Steven Spielberg's Back to the Future. It provided a glimpse of an imagined 2015, when we would all be flying around town in fusion-powered vehicles. The real 2015 is drawing to a close and our cars remain road-bound. This should remind us to make predictions with a degree of humility and care. Yet forecast we must in order to identify investments for a globally diversified multiasset portfolio. For reflections on what we got right and wrong this year, along with over 200 investment predictions for next year, please see our just published Year Ahead 2016.1 It is flying around town in a vehicle we did not imagine 30 years ago – cyberspace.

We still have some important hurdles before year's end – including the US Federal Reserve's expected December rate hike. But as of the time of writing, we can say that 2015 has been a muted year for investors, with global equities returning around 3% in local currency terms, slightly ahead of high grade bonds. The top-performing markets of the Eurozone and Japan have given returns of over 10%, while emerging markets have lost 6%. The S&P 500, though only slightly in positive territory, has now enjoyed its longest rally without a 20% correction since

World War II. As many of you know, we took commodities out of our portfolios in 2014. In 2015 this has been the most disappointing asset class, declining about 23%

For 2016 we expect equities to return around 7%, supported by a moderate acceleration in global growth, rising earnings, healthy corporate balance sheets, and continued central bank stimulus. Yet volatility will likely increase and we hope to seize the opportunities it presents. We enter the new year preferring equities relative to government bonds. We favor stocks in the Eurozone and Japan, where central banks are set to maintain easy monetary policies. This fact also warrants an overweight position in investment grade and European high yield credit.

In addition to creating our outlook for next year, we also attempted a time traveler's jump into the more distant future with our new *Years Ahead* publication. It explores investment themes that we think will play out over coming decades. Although the end of the year is a natural time to focus on the upcoming 12 months, investors can often achieve superior returns by dedicating a portion of their portfolio to longer-term trends.

¹ubs.com/houseview



Private investors have the flexibility to persist with long-term ideas despite periods of volatility.

The global population is expanding, aging, and shifting to urban centers.

Migration from the countryside to the cities will continue in large emerging nations.

The US labor market has largely recovered from the recession following the 2008 financial crisis

A long-term approach remains an important topic for many ultra high net worth clients I speak to, as they seek to preserve and expand their wealth for generations to come. Private investors have an advantage here over professionals; individuals can stick with farsighted ideas through periods of market volatility, while professionals can't control when money flows into and out of their funds.

But to stay the course, one often needs to have conviction in some longer-term growth stories. For the remainder of this letter I want to discuss some of the themes that we find most compelling. This vision of the future also lies behind some of our current equity overweight positions in growth sectors such as technology and healthcare.

So which long-term structural trends to focus on?

In some ways, the *Back to the Future* movies presented an accurate picture of how our world changes. In *Back to the Future II*, Marty McFly travels forward in time to 2015 and meets his own idealized two-child American family having dinner together, but everyone is showing signs of age. While the family structure and the human condition are about the same, technology has rapidly advanced and Hill Valley, McFly's small town, has grown into a city.

Three of the most powerful long-term structural trends that inform our view on investments are the conviction that the world's population is growing robustly, aging rapidly, and increasingly living in cities.


Because demographic changes unfold gradually, there is a lot we can say with confidence about the outlook for population shifts. The UN is predicting an additional 2 billion people by 2050. The population in much of Europe is aging and shrinking while Asia's headcount is on track to swell by close to 900 million – even allowing for a demographic contraction in Japan.

The graying of the world's population, meanwhile, is also a trend of interest to long-term investors. The number of 65 to 69-year-olds globally is likely to more than double by 2050, while the number of people between 90 and 94 may rise fourfold from today, to close to 60 million.

And the increasing urbanization of the world's population, especially in emerging markets, is another trend we can forecast with some confidence. The migration from the country to the city in emerging markets is well documented and well under way; the UN forecasts that Chinese and Indian cities will receive nearly 100 million and 50 million people respectively over the next five years.

Fig. 1: Labor market strength supports the case for the Fed's first rate rise in nine years

Hiring level and unemployment rate in the US, shaded area indicates US recession dates



Source: Bloomberg, UBS, as of October 2015

Demand for water will continue to increase, benefiting companies involved in water treatment and infrastructure.

Businesses focused on boosting agricultural efficiency are also likely to enjoy a bright future.

Rising obesity is among the downsides to urbanization...

... but companies dedicated to weight loss, fitness, and the treatment of obesityrelated diseases stand to gain.

The global population is continuing to expand despite contractions in Europe and Japan.

What long-term investment opportunities do these trends present?

Food and water

The expanding global population – along with improving living standards and emerging market industrialization – is increasing the demand for clean water. We believe that the market for life's most basic commodity will grow at roughly 6% a year for the foreseeable future. That is generating investment opportunities in such areas as water treatment, water management, and water infrastructure.

Then there is food. Every day there are about 200,000 extra mouths to feed. To meet this demand, agricultural efficiency will need to increase – a challenge that can be met through improved irrigation, the design of more resilient crops, and "precision agriculture." This last innovation brings advanced information technology to the most ancient human industry, enabling farmers to collect data and adjust how they cultivate each square foot of land, even to the detail of "plant-by-plant" fertilizing. Companies focused on getting more food out of fewer resources are likely to flourish.


Health

One unfortunate side effect of urbanization and rising emerging market incomes has been greater levels of obesity. Already in 2013 there were 2.1 billion obese or overweight people – more than the total world population of 1927. That figure could continue to rise as cities expand. Urban dwellers tend to walk and bike less, using more motorized transport. More desk jobs tend to promote a sedentary lifestyle while cities have more multinational supermarkets and fast-food chains that sell high-calorie snacks.

Healthy eating has also become a luxury. The cost of fresh fruit and vegetables has risen 90% above the general rate of inflation over the past two decades in leading emerging nations. By contrast, the cost of ready meals fell by one-fifth. Obesity has adverse implications for individuals and society alike.

Still, companies that help reverse bulging waistlines will benefit. The market for their products and services will grow by mid-to-high single-digit rates in our projections. Companies that offer healthier foods and fitness products, as well as those focused on medical products or services to reduce weight or treat diabetes and other obesity-related conditions, are all poised to benefit.

Fig. 2: Demographic growth will not be evenly spread worldwide



Source: United Nations World Population Prospects, UBS, as of July 2015

Rising healthcare spending in emerging nations can be expected to lift the fortunes of drug manufacturers and medical device makers.

Waste disposal facilities will require greater investment as cities expand in emerging nations...

... and firms involved in producing mass transit systems will also enjoy strong demand.

Hurdles remain for 2015, including the Fed rate decision, and high volatility is likely to continue into next year.

The number of people between 65 and 69 years of age is on track to more than double by 2050

In last month's letter, I highlighted advances in cancer treatment and the opportunities they present for investors. On a broader note, emerging nations currently spend less than half as much on healthcare as developed countries, relative to GDP. That gap looks likely to narrow over the coming decade as their wealth increases and populations age; we think that their healthcare spending will climb at roughly double the global rate. Beneficiaries will include drug manufacturers, medical device makers, and medical services providers.

Social infrastructure

The increasing urbanization of the world's population can be expected to propel growth in the waste management and recycling industries. Add in the shorter lifecycles of electronic goods, and we expect global waste volumes to more than double by 2050.


Current disposal facilities are already failing to cope with the existing levels of trash. Less than half of the waste generated in low and middle-income countries is collected, and about 3.5 billion people have no access to garbage disposal at all. Emerging nations are attempting to remedy this as incomes rise, with private firms likely filling the supply gap. Tighter regulations should boost capital expenditures that will benefit a range of companies. For example, our analysis suggests that, between now and 2020, the capacity of China's urban waste incineration treatment sector will rise by close to 130,000 tons...per day. That's the equivalent of the refuse in over 10,000 loaded garbage trucks.

Firms involved in producing mass transit systems also stand to profit. The number of Asians living in megacities (population of over 10 million) is on track to double by 2025. With vehicle ownership doubling every five years, congestion and air-quality problems are intensifying. More governments are looking to beef up public transport facilities. In the coming decade Asian nations are slated to spend 200 billion US dollars on new mass transit systems to combat congestion and air pollution.

The bottom line

From the Fed hiking interest rates to China managing its slowing growth rate, we should be prepared for equity volatility – and to an extent we welcome it. Some of our favorite hedge fund strategies, for example, enjoy greater opportunities in choppy markets that feature large dispersions between stocks.

Fig. 3: The graying of the world's population has important implications for investors



Source: United Nations, UBS. Data as of 2015


The end of the year is a natural time to focus on more long-term investment goals.

The approach of a new year can be a good time for individuals to turn their thoughts to the more distant future and focus on areas where they have a potential edge over institutional investors. I hope this letter sheds light on the opportunities in food, health, and infrastructure offered by some key mega-trends. One thing will not change: a well-diversified portfolio will continue to offer a superior risk-return profile.

Let's make 2016 and beyond healthy and profitable. Even if we still don't have flying cars by 2050, I'm hoping for even more exciting developments – cures for cancer, universal access to clean water, robot butlers, and more *Back to the Future* sequels.

Mark Haefele Global Chief Investment Officer Wealth Management

For comments please contact: ubs-cio-wm@ubs.com



UBS Chief Investment Office WM's investment views are prepared and published by Wealth Management and Retail & Corporate or Wealth Management Americas, Business Divisions of UBS AG (regulated by FINMA in Switzerland), its subsidiary or affiliate ("UBS"). In certain countries UBS AG is referred to as UBS SA. This material is for your information only and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this material were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any prices indicated are current as of the date of the separation of the subject to change without notice. The market prices provided in performance charts and tables are closing prices on the respective principal stock exchange. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result for using different assumptions and/or criteria. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instrument instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barrie

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it This notice is issued by UBS Wealth Management Australia Ltd ABN 50 005 311 937 (Holder of Australian Financial Services No. 231127): This Document is general in nature and does not constitute. personal financial product advice. The Document does not take into account any person's objectives, financial situation or needs, and a recipient should obtain advice from an independent financial adviser and consider any relevant offer or disclosure document prior to making any investment decisions. 2) **Clients of UBS AG:** This notice is issued by UBS AG ABN 47 088 129 613 (Holder of Australian Financial Services Licence No 231087): This Document is issued and distributed by UBS AG. This is the case despite anything to the contrary in the Document. The Document is intended for use only by "Wholesale Clients" as defined in section 761G ("Wholesale Clients") of the Corporations Act 2001 (Cth) ("Corporations Act"). In no circumstances may the Document be made available by UBS AG to a "Retail Client" as defined in section 761G of the Corporations Act. UBS AG's research services are only available to Wholesale Clients. The Document is general information only and does not take into account any person's investment objectives, financial and taxation situation or particular needs. **Bahamas:** This publication is distributed to private clients of UBS (Bahamas) Ltd and is not intended for distribution to persons designated as a Bahamian citizen or resident under the Bahamas Exchange Control Regulations. **Bahrain:** UBS AG is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not Bahrain: Obs AG is a Swiss bank not licensed, supervised or regulated in Bahrain by the Certifal Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, Clients have no protection under local banking and investment services laws and regulations. **Brazzil**: Prepared by UBS Brasil Administradora de Valores Mobiliários Ltda, entity regulated by Comissão de Valores Mobiliários ("CVM") **Canada:** In Canada, this publication is distributed to clients of UBS Wealth Management Canada by UBS Investment Management Canada Inc.. **Dubai**: Research is issued by UBS AG Dubai Branch within the DIFC, is intended for professional clients only and is not for onward distribution within the United Arab Emirates. **France:** This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of € 125.726.944, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution." **Germany:** The issuer under German Law is UBS Deutschland AG, Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Deutschland AG is authorized and regulated by the "Bundesanstalt für Finanzdienstleistungsaufsicht". **Hong Kong:** This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. India: Distributed by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437. Indonesia: This research or publication is not intended and not prepared for purposes of public offering of securities under the Indonesian Capital Market Law and its implementing regulations. Securities mentioned in this material have not been, and will not be, registered under the Indonesian Capital Market Law and Regulations. Israel: UBS AG is registered as a Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd, a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd is a licensed Portfolio Manager which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication shall not replace any investment advice and/or investment marketing provided by a relevant licensee which is adjusted to your personal needs. **Italy:** This publication is distributed to the clients of UBS (Italia) S.p.A., via del vecchio politecnico 3, Milano, an Italian bank duly authorized by Bank of Italy to the provision of financial services and supervised by "Consob" and Bank of Italy. UBS Italia has not participated in the production of the publication and of the research on investments and financial analysis herein contained. Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. **Luxembourg:** This publication is not intended to constitute a public offer under Luxembourg law, but might be made available for information purposes to clients of UBS (Luxembourg) S.A., 33A avenue J.F. Kennedy, L-1855 Luxembourg, R.C.S. Luxembourg B 11142, a regulated bank under the supervision of the "Commission de Surveillance du Secteur Financier" (CSSF), to which this publication has not been submitted for approval. Mexico: This document has been distributed by UBS Assores México, S.A. de C.V., a company which is not part of UBS Grupo Financiero, S.A. de C.V. or of any other Mexican financial group and whose obligations are not guaranteed by any third party. UBS Assores México, S.A. de C.V. does not guarantee any yield whatsoever. **Netherlands**: This publication is not intended to constitute a public offering or a comparable solicitation under Dutch law, but might be made available for information purposes to clients of UBS Bank (Netherlands) B.V., a regulated bank under the supervision of "De Nederlansche Bank" (DNB) and "Autoriteit Financiële Markten" (AFM), to which this publication has not been submitted for approval. **New Zealand**: This notice is distributed to clients of UBS Wealth Management Australia Limited ABN 50 005 311 937 (Holder of Australian Financial Services Licence No. 231127), Chifley Tower, 2 Chifley Square, Sydney, New South Wales, NSW 2000, by UBS Wealth Management Australia Ltd. You are being provided with this UBS publication or material because you have indicated to UBS that you are a client certified as a wholesale investor and/or an eligible investor ("Certified Client") located in New Zealand. This publication or material is not intended for clients who are not Certified Clients ("Non-Certified Clients"), and if you are a Non-Certified Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective directors, officers, agents and advisers (each a "Relevant Person") for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Saudi Arabia**: This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi Arabian closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority of Saudi Arabia. Singapore: Please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. **Spain:** This publication is distributed to clients of UBS Bank, S.A. by UBS Bank, S.A., a bank registered with the Bank of Spain. **Taiwan:** This material is provided in accordance with laws of Taiwan, in agreement with or at the request of clients. **UAE:** This research report is not intended to constitute an offer, sale or delivery of shares or other securities under the laws of the United Arab Emirates (UAE). The contents of this report have not been and will not be approved by any authority in the United Arab Emirates including the UAE Central Bank or Dubai Financial Authorities, the Emirates Securities and Commodities Authority, the Dubai Financial Market, the Abu Dhabi Securities market or any other UAE exchange. **UK**: Approved by UBS AG, authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to private clients of UBS London in the UK. Where products or services are provided from outside the UK, they will not be covered by the UK regulatory regime or the Financial Services Compensation Scheme. **USA**: This document is not intended for distribution into the US and / or to US persons. UBS Securities LLC is a subsidiary of UBS AG and an affiliate of UBS Financial Services Inc., UBS Financial Services Inc. is a subsidiary of UBS AG.

Version 05/2015

© UBS 2015. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.